INFORMAZIONI SU QUESTO EPISODIO
BUFFALO, NY - November 4, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on November 2, 2026, titled “Survival factors in lung cancer patients with mutations in the PROS1, SERPINC1, F2, and F5 genes.”
The study identified associations between genes involved in blood coagulation and survival outcomes in patients with lung cancer. Analyzing genetic and clinical data from 1,419 patients, the researchers found that the prognostic significance of four coagulation-related genes varied according to mutation status, tumor location and other clinical characteristics. The findings suggest that these genes may provide additional information for understanding lung cancer prognosis, although their clinical usefulness remains to be established.
The research was led by first and corresponding author Ryan Brownlee, affiliated with the Medical College of Georgia at Augusta University.
Lung cancer remains a leading cause of cancer-related death worldwide. Although advances in targeted therapies, immunotherapy and molecular diagnostics have improved outcomes for some patients, survival varies considerably depending on disease stage, tumor characteristics and treatment response. Identifying additional biological factors associated with prognosis could help researchers better understand these differences.
One area of growing interest is the relationship between cancer and blood coagulation. Patients with malignancies are at increased risk of abnormal blood clots, known as cancer-associated thrombosis. Beyond causing potentially serious complications, coagulation-related proteins can influence inflammation, tumor growth and interactions between malignant cells and their surrounding tissues.
The researchers focused on four genes associated with thrombophilia, an increased tendency to develop blood clots: PROS1, SERPINC1, F2 and F5. These genes encode proteins involved in regulating the coagulation cascade, and alterations in their function have been linked to thrombotic disorders.
Full press release - https://www.oncotarget.com/news/pr/coagulation-related-genes-and-tumor-location-linked-to-lung-cancer-survival/
DOI - https://doi.org/10.18632/oncotarget.28914
Correspondence to - Ryan Brownlee - Rbrownlee@augusta.edu
Abstract video - https://www.youtube.com/watch?v=3leoNrmo3Ag
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28914
Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/
Keywords - cancer, F5, PROS1, SERPINC1, lung cancer, thrombophilia
To learn more about the journal, please visit https://www.oncotarget.com and connect with us:
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh
MEDIA@IMPACTJOURNALS.COM
The study identified associations between genes involved in blood coagulation and survival outcomes in patients with lung cancer. Analyzing genetic and clinical data from 1,419 patients, the researchers found that the prognostic significance of four coagulation-related genes varied according to mutation status, tumor location and other clinical characteristics. The findings suggest that these genes may provide additional information for understanding lung cancer prognosis, although their clinical usefulness remains to be established.
The research was led by first and corresponding author Ryan Brownlee, affiliated with the Medical College of Georgia at Augusta University.
Lung cancer remains a leading cause of cancer-related death worldwide. Although advances in targeted therapies, immunotherapy and molecular diagnostics have improved outcomes for some patients, survival varies considerably depending on disease stage, tumor characteristics and treatment response. Identifying additional biological factors associated with prognosis could help researchers better understand these differences.
One area of growing interest is the relationship between cancer and blood coagulation. Patients with malignancies are at increased risk of abnormal blood clots, known as cancer-associated thrombosis. Beyond causing potentially serious complications, coagulation-related proteins can influence inflammation, tumor growth and interactions between malignant cells and their surrounding tissues.
The researchers focused on four genes associated with thrombophilia, an increased tendency to develop blood clots: PROS1, SERPINC1, F2 and F5. These genes encode proteins involved in regulating the coagulation cascade, and alterations in their function have been linked to thrombotic disorders.
Full press release - https://www.oncotarget.com/news/pr/coagulation-related-genes-and-tumor-location-linked-to-lung-cancer-survival/
DOI - https://doi.org/10.18632/oncotarget.28914
Correspondence to - Ryan Brownlee - Rbrownlee@augusta.edu
Abstract video - https://www.youtube.com/watch?v=3leoNrmo3Ag
Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28914
Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/
Keywords - cancer, F5, PROS1, SERPINC1, lung cancer, thrombophilia
To learn more about the journal, please visit https://www.oncotarget.com and connect with us:
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh
MEDIA@IMPACTJOURNALS.COM
Inglese
Stati Uniti
TRASCRIZIONE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di Oncotarget.
ALTRI EPISODI IN QUESTO PODCAST
BUFFALO, NY – September 28, 2026 – A new #editorial was #published in Volume 17 of Oncotarget on September 23, 2026, titled “Gut feeling: Microbes at the heart of cancer therapy.”
The article examines how the human microbiome may influence cancer development, treatment response and emerging preci…
BUFFALO, NY – September 9, 2026 – A new #review was #published in Volume 17 of Oncotarget on September 8, 2026, titled “Re-expression of MHC-I to treat CNS cancers.”
The review examines emerging strategies to restore major histocompatibility complex class I (MHC-I) expression in cancers of the ce…
BUFFALO, NY – September 17, 2026 – A new #commentary was #published in Volume 17 of Oncotarget on September 11, 2026, titled “Are both COVID-19 and COVID-19 vaccines associated with cancer?”
The paper was authored by Raphael Lataster, an independent researcher at the University of Sydney, and res…
Head and neck squamous cell carcinoma (HNSCC) can return even after patients complete surgery, radiation, chemotherapy, or combinations of these treatments. Preventing recurrence therefore remains an important challenge in head and neck cancer care. Human papillomavirus (HPV), particularly HPV type…
Cancer cells do not grow in isolation. Their ability to survive and form tumors depends partly on how they interact with immune cells in the surrounding tumor microenvironment. Melanoma is particularly responsive to immune-based mechanisms, making it important to understand the molecular processes …
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da Oncotarget Podcast, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
